Gi coupling to cyclic guanine monophosphate-nitric oxide (4) . Although beta-adrenergic stimulation is a major compensatory mechanism in the acute setting such as traumatic hypovolemia, it appears to worsen ventricular function and outcome in conditions with limited metabolic and physiological reserves, such as heart failure (HF) (1) . Accordingly, beta-blocking agents were developed to partially antagonize betaadrenergic "excess" of norepinephrine at the cardiomyocyte level (1) .
Since the first discovery of beneficial effects of beta-blocker therapy in a small case series While the previously mentioned investigational approaches used polymerase chain reaction (PCR) to gain valuable information about the molecular effects of beta-blocking agents on specific candidate genes, our group sought to expand the current knowledge by applying microarrays, a technology that evaluates expression levels of all genes in a given individual. Therefore, it allows the discovery of new genes and pathways in a more comprehensive approach (13) (14) (15) (16) (17) (18) that has proven useful to delineate diagnosis and prognosis in HF populations (15, 16, 18) . While typically only genes of interest or candidate genes are investigated with polymerase chain reaction, microarray technology analyzes the entire transcriptome of about 30,000 genes in 1 experiment (19) and, therefore, provides a less biased approach of gene discovery.
METHODS PATIENT POPULATION.
To identify genes that undergo expression changes during treatment with beta-blocking agents, we first analyzed endomyocardial biopsies (EMBs) obtained from patients with new-onset HF (n ¼ 43), who were treated with beta-blockers (n ¼ 30) versus alternative standard therapy (n ¼ 13). This cohort has been previously described and analyzed for prognostic information (15) . EMBs were obtained from a biorepository containing samples from patients with new-onset HF (15, 16, 18) . In brief, transvenous EMBs were obtained from the right interventricular septum and 
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A P R I L 2 0 1 6 : 1 0 7 -2 1 immediately flash frozen in liquid nitrogen for storage and subsequent microarray analysis. All patients gave their written informed consent to participate in this study. After identifying genes that were affected by carvedilol or metoprolol, we sought to identify transcriptomic changes specifically related to improved outcomes. Therefore, in a case-control fashion on the basis of the same baseline parameters as for our first analysis, we investigated gene expression changes that were unique to patients who were responsive to beta-blocking agents. For this second analysis, within the previously described participants who received beta-blocking agents, we identified a group with good prognosis (n ¼ 17) and a group with poor prognosis (n ¼ 13) (Figure 1) . Good prognosis was defined as event-free survival for at least 5 years after diagnosis of HF. Poor prognosis was defined as having an event within 2 years after symptom onset. Events included death, requirement for left ventricular assist device placement, or cardiac transplant (15) .
New
RIBONUCLEIC ACID ISOLATION FROM EMBs. We extracted and hybridized total RNA from EMBs as previously described (15) (16) (17) . All EMBs were obtained We analyzed a cohort of 43 patients with idiopathic dilated cardiomyopathy for molecular changes that are induced by beta-blocking agents. Among the patients on beta-blocking agents, we selected patients with poor (n ¼ 13) versus good prognosis (n ¼ 17) to identify gene expression changes in patients who improved during therapy with beta-blockers. Twothirds of the data were used as a train set to develop the biomarker (poor prognosis n ¼ 8; good prognosis: n ¼ 11) and one-third of the data was used as an independent test set for validation of the molecular signature (poor prognosis: n ¼ 5; good prognosis: n ¼ 6). Organ-and species-specific pre-filtering was performed before network analysis to identify pathways that are truly inter-related within the human heart.
To obtain a false discovery rate of a pathway, the p value was adjusted for multiple comparisons. For that purpose, the software applies a false discovery rate adjustment. This adjustment of the p value of the enrichment of a pathway takes into account the number of tests that are being performed during the enrichment analysis. In addition, a z score was calculated for each network, which reflects the saturation with genes from the experiment. A high z score indicates a network that contains a large amount of genes from the experiment, therefore suggesting that this particular network was significantly affected.
The g score takes into account how many canonical pathways were involved to create the network by modifying the z score on the basis of the number of linear canonical pathway fragments contained within the network. A network with a high g score is saturated with objects from the investigated gene list and contains a large number of canonical pathway fragments.
To develop a marker that predicts responsiveness to beta-blockers, we applied Misclassification Penal- In support vector machine algorithms for classification, the input data is plotted as 2 vectors in an n-dimensional space, and a virtual hyperplane is created that best separates the 2 phenotypes. This hyperplane is then used to classify samples with unknown phenotypes.
We developed a molecular signature in two-thirds of the data using 5-fold cross validation and performed additional validation in an independent sample that contained the other one-third of the data.
To evaluate if distinct models are generated from additional random splits, we performed 50 random divisions to develop individual classification models, which were then validated in 10 independent splits. Furthermore, we calculated mean sMiPP for every given gene model, an additional parameter for performance, which approximates 1 with increasing accuracy. Table 1 illustrates baseline variables of the initial set of samples in our first analysis including patients with new-onset HF treated with beta-blocking agents versus alternative standard therapy. There were no significant differences between the 2 groups (evaluated by Student t test and Fisher exact test). Importantly, the cohort was balanced between male and female subjects (70% vs. 62%). Hemodynamic parameters, including EF, left ventricular internal dimension-diastole, pulmonary artery pressure, and pulmonary capillary wedge pressure, were similar between groups. In both patient populations, a predominance of angiotensin-converting enzyme inhibitor and diuretic agent use was observed. A predictive molecular signature of therapy responsiveness was then developed in a train set, which contained twothirds of the cohort treated with beta-blocking agents. One third of data was used as independent test set, in which accuracy of the biomarker was evaluated. Table 2 depicts baseline conditions of the train set (two-thirds of the cohort taking Table 4 represent the percentage of objects on that specific particular subnetwork that have been linked to that GO process.
RESULTS
Similarly, the p value listed next to the percentage is calculated on the basis of the total number of objects on that particular subnetwork, the number of those objects on that subnetwork associated with the GO process, and of the objects associated with that GO process in the database. It uses the same calculation method as the other p values throughout MetaCore (hypergeometric distribution).
MOLECULAR SIGNATURE TO PREDICT RESPONSIVENESS TO BETA-BLOCKING AGENTS IN PATIENTS WITH
NEW-ONSET HF. MiPP classification software was used to identify a transcriptomic biomarker containing the minimal set of genes necessary to distinguish patients responsive to beta-blockers from nonresponsive patients (22) . A set of 4 transcripts was identified, which predicted therapy responsiveness with very high accuracy (mean error: 0.04, mean sMiPP: 0.89). These included transcripts of the genes ARHGEF1, ALP1, ZNF404, and the transcript 239497_at (Affymetrix ID, not yet characterized). The 6 most robust molecular signatures predictive for response to beta-blockers are illustrated in Table 5 . Tables 6 and 7 . 
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Abbreviations as in Table 1 .
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Among the genes of therapy responsiveness was Rho Guanine Nucleotide Exchange Factor, which is a key player in antiapoptotic function and in a metabolic pathway that regulates contraction and actinmyosin interaction. The pathway is illustrated in Figure 4 .
EVALUATION OF RECENTLY SUGGESTED CANDIDATE GENES AFFECTED BY BETA-BLOCKING AGENTS, WHICH MAY BE CAUSATIVE FOR IMPROVED HEART
FUNCTION. Finally we tested a set of genes that had been recently related to improvement of EF during beta-blocker therapy (10). Lowes et al. (10) found MYH6 and SERCA2/ATP2A2ase to be overexpressed and MYH7 to be down-regulated in patients with an improvement of EF by at least 5% while on beta-blocking agents. When we evaluated those candidate genes in our population treated with beta-blocking agents, we similarly found overexpression of MYH6 (FC 1.3, q value ¼ 0%) and SERCA2/ATPA2 (FC 1.4, q value ¼ 0%) in patients on beta-blockers and good prognostic outcome versus poor outcome. However, there was also slight overexpression of MYH7 (FC 1.2, q value ¼ 0%) in patients with good prognostic outcome.
DISCUSSION
The major new finding of this study is the discovery of a molecular signature that identified patients with favorable outcomes receiving beta-adrenergic antagonist therapy for new-onset HF. We hypothesize that this signature can be used as a clinical biomarker.
Given the mentioned limitations of this study, further prospective trials are necessary to test this hypothesis, in particular if this molecular signature exists in patients prior to initiation of beta-blocker therapy.
We have previously employed transcriptomic-based biomarkers (TBBs) to establish diagnosis and prognosis in patients with new-onset HF (15, 16, 18) . The present findings show the utility of this approach for pharmacogenomic personalized medicine, and as such, support the use of TBBs for advancing precision medicine.
The success of beta-blocking therapy in the treatment of HF has been attributed to molecular alterations of pathways in the heart, including reverse cardiac remodeling, as well as enhancement of contractile and calcium-channel proteins. Lowes et al.
(10) discovered that treatment with beta-blockers Heidecker et al. 
Continued on the next page J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 3 , 2 0 1 6
A P R I L 2 0 1 6 : 1 0 7 -2 1 Heidecker et al.
Molecular Effects of Beta-Blocking Agents in the Heart

J A C C : B A S I C T O T R A N S L A T I O N A L S C I E
N C E V O L . 1 , N O . 3 , 2 0 1 6
Molecular Effects of Beta-Blocking Agents in the Heart
A P R I L 2 0 1 6 : 1 0 7 -2 1 
Heidecker et al. 
FIGURE 3 Heat Map of Samples From All Patients With IDCM
When we applied this unsupervised clustering algorithm, samples from patients on beta-blocking agents were grouped in a classification tree (highlighted in a dotted square) that was very distinct from patients who received alternative therapy. Each column represents a patient sample, and each row corresponds to a gene. Down-regulated genes are depicted in red, whereas up-regulated genes are labeled in blue.
Heidecker et al. Abbreviations as in Table 3 .
ventricle. Animal studies showed similar findings for right versus left ventricle (24) (25) (26) .
When we performed MetaCore pathway analysis, we identified 15 molecular pathways that were activated during treatment with metoprolol or carvedilol.
Pathways that were overexpressed with highest significance values were cellular metabolic processes involving phosphate metabolism, cellular iron homeostasis, and developmental processes.
We then went on to investigate if transcriptomic biomarkers derived from heart biopsies can be used to Table 3 .
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FIGURE 4 Signaling Pathway of Rho Guanine Nucleotide Exchange Factor
Important functions of this pathway involve antiapoptotic actions and regulation of actin-myosin interaction. Abbreviations as in Table 3 .
the most comprehensive study to date investigating the effects of beta-blocking agents on the gene expression level and the first, to the best of our knowledge, that has identified a transcriptomic biomarker of therapy responsiveness in this drug class. Mechanistic animal studies will be necessary in the future to evaluate which of the changes during therapy were causative.
Also it warrants mention that it is difficult to establish a clear cut-off for each individual gene to determine which FC in gene expression has significant effect on its function downstream, as some genes are regulated more tightly than others. This issue has been previously discussed in the published data (15, 16, 27) . Because part of the purpose of this study was gene discovery, we chose an inclusive approach with an FC cutoff of 1.2 and q value <5% to define significance.
Finally, it should be mentioned that some of the molecular differences that were observed in patients treated with beta-blocking agents versus alternative therapy may reflect changes secondary to comorbidities that prevented patients from being on beta- TRANSLATIONAL OUTLOOK: The transcriptomicbased biomarker described in this study can be potentially used by practitioners caring for these patients to help monitor patient's response to drugs.
This approach is similar to other types of precision medicine approaches that have been developed to predict clinical trajectory independent of drug treatment or to enhance the diagnostic accuracy in myocarditis.
